Dominant-negative hypoxia-inducible factor-1α reduces tumorigenicity of pancreatic cancer cells through the suppression of glucose metabolism

American Journal of Pathology

Volumn 162, Issue 4, 2003, Pages 1283-1291

  Chen, Jian ^a,b   Zhao, Songji ^b   Nakada, Kunihiro ^b   Kuge, Yuji ^b   Tamaki, Nagara ^b   Okada, Futoshi ^a   Wang, Jingxin ^a   Shindo, Masanobu ^a   Higashino, Fumihiro ^a   Takeda, Kohji ^b   Asaka, Masahiro ^b   Katoh, Hiroyuki ^b   Sugiyama, Toshio ^b   Hosokawa, Masuo ^a   Kobayashi, Masanobu ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DOMINANT NEGATIVE HYPOXIA INDUCIBLE FACTOR 1ALPHA; FRUCTOSE BISPHOSPHATE ALDOLASE; FRUCTOSE BISPHOSPHATE ALDOLASE ISOENZYME; GLUCOSE; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 2; HYPOXIA INDUCIBLE FACTOR 1ALPHA; UNCLASSIFIED DRUG;

ADAPTATION; ANAEROBIC METABOLISM; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CARCINOGENICITY; CELL COUNT; CELL GROWTH; CELL HYPOXIA; CELL SURVIVAL; CONTROLLED STUDY; GENE DISRUPTION; GENE EXPRESSION; GENE FUNCTION; GENETIC TRANSFECTION; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; GROWTH INHIBITION; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCID MOUSE;

EID: 0344608877     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)63924-7     Document Type: Article

References (41)

1. Vaupel P, Kallinowski F, Okunieff P: Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 1989, 49:6449-6465
2. Richard DE, Berra E, Pouyssegur J: Angiogenesis: how a tumor adapts to hypoxia. Biochem Biophys Res Comm 1999, 266:718-722
3. Wang GL, Jiang BH, Rue EA, Semenza GL: Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 1995, 92:5510-5514
4. Guillemin K, Krasnow MA: The hypoxic response: huffing and HIFing. Cell 1997, 89:9-12
5. Salceda S, Caro J: Hypoxia-inducible factor 1α (HIF-1 a) protein is rapidly degraded by the ubiquitin/proteasome system under normoxic conditions. J Biol Chem 1997, 272:22642-22647
6. Blancher C, Harris AL: The molecular basis of hypoxia response pathway: tumor hypoxia as a therapy target. Cancer Metastasis Rev 1998, 17:187-194
7. Dang CV, Semenza GL: Oncogenic alterations of metabolism. Trends Biochem Sci 1999, 24:68-72
8. Semenza GL: Expression of hypoxia-inducible factor 1: mechanisms and consequences. Biochem Pharmacol 2000, 59:47-53
9. Ryan HE, Lo J, Johnson RS: HIF-1 alpha is required for solid tumor formation and embryonic vascularization. EMBO J 1998, 17:3005-3015
10. Maxwell PH, Dachs GU, Gleadle JM, Nicholls LG, Harris AL, Stratford IJ, Hankinson O, Pugh CW, Ratcliffe PJ: Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci USA 1997, 94:8104-8109
11. Hockel M, Vaupel P: Biological consequences of tumor hypoxia. Semin Oncol 2001, 28:36-41
12. Akakura N, Kobayashi M, Horiuchi I, Suzuki A, Wang J, Chen J, Niizeki H, Kawamura K, Hosokawa M, Asaka M: Constitutive expression of hypoxia-inducible factor-1a (HIF-1a) renders pancreatic cancer cells resistant to apoptosis induced by hypoxia and nutrient deprivation. Cancer Res 2001, 61:6548-6554
13. Warburg OH: On respiratory impairment in cancer cells. Science 1956, 124:269-270
14. Carmeliet P, Dor Y, Herbert JM, Fukumura D, Brusselmans K, Dewerchin M, Neeman M, Bono F, Abramovitch R, Maxell P, Koch CJ, Ratcliffe P, Moons F, Jain RK, Collen D, Keshet E: Role of HIF-1a in hypoxia-mediated apoptosis, cell proliferation and tumor angiogenesis. Nature 1998, 394:485-490
15. Ryan HE, Poloni M, McNulty W, Elson D, Gassmann M, Arbeit JM, Johnson RS: Hypoxia-inducible factor-1 alpha is a positive factor in solid tumor growth. Cancer Res 2000, 60:4010-4015
16. Kung AL, Wang S, Klco JM, Kaelin Jr WG, Livingston DM: Suppression of tumor growth through disruption of hypoxia-inducible transcription. Nat Med 2000, 6:1335-1340
17. An WG, Mookerjee ZM, Sutter CH, Artemov D, Zeng Q, Dillehay LE, Madan A, Semenza GL, Bedi A: Stabilization of wild-type p53 by hypoxia-inducible factor 1a. Nature 1998, 392:405-408
18. Merral NW, Plevin R, Gould GW: Growth factors, mitogens, oncogenes and the regulation of glucose transport. Cell Signal 1993, 5:667-675
19. Mally MI, Otonkoski T, Lopez AD, Hayek A: Developmental gene expression in the human fetal pancreas. Pediatr Res 1994, 36:537-544
20. Asaka M, Nagase K, Miyazaki T, Alpert E: Radioimmunoassay of aldolase A. Determination of normal serum levels and increased serum concentration in cancer patients. Cancer 1983, 51:1873-1878
21. Kobayashi M, Nagayasu H, Hamada J, Takeichi N, Hosokawa M: ONO-4007, a new synthetic lipid A derivative, induces differentiation of rat myelomonocytic leukemia cells in vitro and in vivo. Exp Hematol 1994, 22:454-459
22. Hockel M, Vaupel P: Tumor hypoxia: definitions and current clinical biologic, and molecular aspects. J Natl Cancer Inst 2001, 93:266-276
23. Choi S, Kobayashi M, Wang J, Habellhah H, Okada F, Hamada J, Moriuchi T, Totsuka Y, Hosokawa M: Activated leukocyte cell adhesion molecule (ALCAM) and annexin II are involved in the metastatic progression of tumor cells after chemotherapy with adriamycin. Clin Exp Metastasis 2000, 18:45-50
24. Wang J, Kobayashi M, Han M, Choi S, Takano M, Hashino S, Tanaka J, Kondoh T, Kawamura K, Hosokawa M: MyD88 is involved in the signalling pathway for Taxol-induced apoptosis and TNF-alpha expression in human myelomonocytic cells. Br J Haematol 2002, 118:638-645
25. Halterman MW, Miller CC, Federoff HJ: Hypoxia-inducible factor-1alpha mediates hypoxia-induced delayed neuronal death that involves p53. J Neurosci 1999, 19:6818-6824
26. Zhao S, Kuge Y, Tsukamoto E, Mochizuki T, Kato T, Hisokawa K, Hosokawa M, Kohanawa M, Tamaki N: Effects of insulin and glucose loading on FDG uptake in experimental malignant and inflammatory lesions. Eur J Nucl Med 2001, 28:730-735
27. Vincent KA, Shyu KG, Luo Y, Magner M, Tio RA, Jiang C, Goldberg MA, Akita GY, Gregory RJ, Isner JM: Angiogenesis is induced in a rabbit model of hindlimb ischemia by naked DNA encoding an HIF-1alpha/VP16 hybrid transcription factor. Circulation 2000, 102:2255-2261
28. Tooronjian SA, Mulhorando GK, Jewett DM, Bachlor MA, Kilbourn MR: Routine production of 2-deoxy-2-[18F] fluoro-D-glucose by direct nucleophilic exchange on a quaternary 4-aminopyridinium resin. Nucl Med Biol 1990, 17:273-279
29. Delbeke D, Rose DM, Chapman WC, Pinson CW, Wright JK, Beauchamp RD, Shyr Y, Leach SD: Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma. J Nucl Med 1999, 40:1784-1791
30. Makino Y, Cao R, Svensson K, Bertillson G, Asman M, Tanaka H, Cao Y, Berkenstam A, Poellinger L: Inhibitory PAS domain is a negative regulator of hypoxia-induced gene expression. Nature 2001, 414:550-554
31. Fukumura D, Xavier R, Sugiura T, Chen Y, Park E, Lu N, Selig M, Nielsen G, Taksir T, Jain RK, Seed B: Tumor induction of VEGF promoter in stromal cells. Cell 1998, 94:715-725
32. Tsuzuki Y, Fukumura D, Oosthuyse B, Koike C, Carmeliet P, Jain RK: Vascular endothelial growth factor (VEGF) modulation by targeting hypoxia-inducible factor-1a→hypoxia response element→VEGF cascade differentially regulates vascular response and growth rate in tumors. Cancer Res 2000, 60:6248-6252
33. Nolop KB, Rhodes CG, Brudin LH, Beaney RP, Krausz T, Jones T, Hughes JM: Glucose utilization in vivo by human pulmonary neoplasms. Cancer 1998, 60:2682-2689
34. Gatenby RA: The potential role of transformation-induced metabolic changes in tumor-host interaction. Cancer Res 1995, 55:4151-4156
35. Ak I, Stokkel MP, Pauwels EK: Positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose in oncology. Part II. The clinical value in detecting and staging primary tumours. J Cancer Res Clin Oncol 2000, 126:560-574
36. Higashi T, Tamaki N, Honda T, Torizuka T, Kimura T, Inokuma T, Ohshio G, Hosotani R, Imamura M, Konishi J: Expression of glucose transporters in human pancreatic tumors compared with increased FDG accumulation in PET study. J Nucl Med 1997, 38:1337-1344
37. Ebert BL, Firth JD, Ratcliffe PJ: Hypoxia and mitochondrial inhibitors regulate expression of glucose transporter-1 via distinct Cis-acting sequences. J Biol Chem 1995, 270:29083-29090
38. Seagroves TN, Ryan HE, Lu H, Wouters BG, Knapp M, Thibault P, Laderoute K, Johnson RS: Transcription factor HIF-1 is a necessary mediator of the Pasteur effect in mammalian cells. Mol Cell Biol 2001, 21:3436-3444
39. Eguchi Y, Srinivasan A, Tomaselli KJ, Shimizu S, Tsujimoto Y: ATP-dependent steps in apoptotic signal transduction. Cancer Res 1999, 59:2174-2181
40. Plas DR, Talapatra S, Edinger AL, Rathmell JC, Thompson CB: Akt and Bcl-xL promote growth factor-independent survival through distinct effects on mitochondrial physiology. J Biol Chem 2001, 276:12041-12048
41. Gottlob K, Majewski N, Kennedy S, Kandel E, Robey RB, Hay N: Inhibition of early apoptotic events by Akt/PKB is dependent on the first committed step of glycolysis and mitochondrial hexokinase. Genes Dev 2001, 15:1406-1418